These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 24984571)

  • 1. Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia.
    Mathisen MS; Kantarjian HM; Cortes J; Jabbour EJ
    Blood Rev; 2014 Sep; 28(5):179-87. PubMed ID: 24984571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.
    Jabbour E; Kantarjian H; Cortes J
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):323-34. PubMed ID: 25971713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic myeloid leukemia: First-line drug of choice.
    Jabbour E
    Am J Hematol; 2016 Jan; 91(1):59-66. PubMed ID: 26769227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.
    Hochhaus A; Ernst T; Eigendorff E; La Rosée P
    Ann Hematol; 2015 Apr; 94 Suppl 2():S133-40. PubMed ID: 25814079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
    Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Irvine E; Williams C
    Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Rochau U; Sroczynski G; Wolf D; Schmidt S; Jahn B; Kluibenschaedl M; Conrads-Frank A; Stenehjem D; Brixner D; Radich J; Gastl G; Siebert U
    Leuk Lymphoma; 2015; 56(8):2315-25. PubMed ID: 25393806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia.
    Rabian F; Lengline E; Rea D
    Curr Hematol Malig Rep; 2019 Dec; 14(6):492-500. PubMed ID: 31760572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
    Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?
    Eskazan AE; Ozmen D
    Expert Rev Hematol; 2017 Jul; 10(7):583-586. PubMed ID: 28586242
    [No Abstract]   [Full Text] [Related]  

  • 12. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
    Massimino M; Stella S; Tirrò E; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Tomarchio C; DI Raimondo F; Manzella L
    Anticancer Res; 2020 May; 40(5):2457-2465. PubMed ID: 32366389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
    Jabbour E; Lipton JH
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):646-56. PubMed ID: 24095296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
    Bhalla S; Tremblay D; Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors.
    Jabbour E; Cortes J; Kantarjian H
    Cancer; 2011 Mar; 117(5):897-906. PubMed ID: 20945321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial treatment for patients with CML.
    Goldman JM
    Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison.
    Firwana B; Sonbol MB; Diab M; Raza S; Hasan R; Yousef I; Zarzour A; Garipalli A; Doll D; Murad MH; Al-Kali A
    Int J Cancer; 2016 Mar; 138(6):1545-53. PubMed ID: 26455714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequencing treatment in chronic myeloid leukemia: the first choice may be the hardest.
    Heaney ML
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):502-8. PubMed ID: 25356574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
    Pophali PA; Patnaik MM
    Cancer J; 2016; 22(1):40-50. PubMed ID: 26841016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.
    Khoury HJ; Bixby DL
    Leuk Lymphoma; 2015 Mar; 56(3):568-76. PubMed ID: 24884315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.